Core Viewpoint - Dezheng Health is actively developing an innovative drug project, WYY, aimed at treating stroke as a neuroprotective agent, with plans for IND application submission within the year [2] Group 1: Product Development - WYY is a self-developed innovative drug project by the company [2] - The company is preparing for the IND application for the WYY injection form and plans to submit it within the current year [2] - The company is also advancing research on the sublingual tablet form of WYY [2] Group 2: Regulatory Compliance - The company will fulfill disclosure obligations in accordance with regulatory requirements based on the progress of related matters [2]

德展健康（000813.SZ）8月11日在投资者互动平台表示，WYY是公司自主研发的一类创新药项目，是 主要用于治疗脑卒中的神经保护剂。目前公司正在进行WYY注射剂型的IND申报准备，计划本年度内 提交IND申请，同时公司正积极推进WYY舌下片剂型的研究。后续公司将根据相关事项进展情况，依 据法规要求及时履行披露义务。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：WYY是公司自主研发的一类创新药项目？请问WYY一 类创新药进展情况如何？ ...